Pfizer Corporation

Timothy Michael Lukas

W James Huang

Jonathan Richard Lillis

Stephen Richard Wicks

Kevin Richard Back

Michael Cram

Aidan James Harper

Sumit Luthra

Valerie Denise Harding

Snezana Milojevic

The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Formulations of a PI3K/mTOR-inhibitor for intravenous administration

The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Formulations of a PI3K/mTor-inhibitor for intravenous administration

Antiparasitic formulations

Long-acting antiparasitic formulations of doramectin, suitable for injection, are described herein.

Antiparasitic formulation

Growing community of inventors

Sandwich, United Kingdom

Timothy Michael Lukas